82,596 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Acquired by Wellington Management Group LLP

Wellington Management Group LLP acquired a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 82,596 shares of the company's stock, valued at approximately $687,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. State Street Corp boosted its holdings in shares of Amneal Pharmaceuticals by 3.8% during the third quarter. State Street Corp now owns 3,514,721 shares of the company's stock worth $29,242,000 after purchasing an additional 127,753 shares during the period. Quadrature Capital Ltd bought a new position in Amneal Pharmaceuticals during the 3rd quarter valued at approximately $169,000. Polar Asset Management Partners Inc. lifted its holdings in Amneal Pharmaceuticals by 122.5% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 393,000 shares of the company's stock worth $3,270,000 after buying an additional 216,400 shares during the period. Bellevue Group AG grew its position in shares of Amneal Pharmaceuticals by 21.8% in the 3rd quarter. Bellevue Group AG now owns 76,414 shares of the company's stock worth $636,000 after buying an additional 13,654 shares during the last quarter. Finally, Walleye Capital LLC purchased a new position in shares of Amneal Pharmaceuticals during the third quarter valued at approximately $1,095,000. Institutional investors own 31.82% of the company's stock.

Insider Transactions at Amneal Pharmaceuticals

In other news, SVP Jason B. Daly sold 43,657 shares of the firm's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the transaction, the senior vice president now directly owns 13,665 shares in the company, valued at $117,655.65. This trade represents a 76.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 26.56% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. StockNews.com cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday. Piper Sandler lifted their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a research note on Monday, November 11th. Truist Financial increased their price target on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 target price on the stock in a report on Friday, September 6th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $10.00.

Amneal Pharmaceuticals Price Performance

NASDAQ:AMRX traded up $0.03 during mid-day trading on Friday, hitting $7.78. 1,657,823 shares of the company's stock were exchanged, compared to its average volume of 1,382,215. The company has a market cap of $2.41 billion, a PE ratio of -11.44 and a beta of 1.12. Amneal Pharmaceuticals, Inc. has a one year low of $5.01 and a one year high of $9.48. The business has a fifty day moving average price of $8.42 and a 200 day moving average price of $7.94.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.